Abstract
Ublituximab, an intravenous glycoengineered chimeric anti-CD20 IgG1 monoclonal antibody (mAb), is a new FDA-approved treatment for relapsing forms of ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
